The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. 2512
Main Authors Heiss, M. M., Ströhlein, M. A., Bokemeyer, C., Arnold, D., Parsons, S. L., Ott, M. G., Schulze, E., Lindhofer, H., Seimetz, D., Hennig, M.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.2512